Rapid oral desensitisation procedure in clopidogrel hypersensitivity

Netherlands Heart Journal

Volumn 16, Issue 1, 2008, Pages 21-23

  Oppedijk, B ^a   Odekerken, D A M ^a   Van Der Wildt, J J ^a   Melissant, C F ^a  

^a Department of Orthopaedic Surgery   (Netherlands)

Author keywords

Clopidogrel hypersensitivity; Desensitisation; Stent; Thrombosis

Indexed keywords

ANTIHISTAMINIC AGENT; CLOPIDOGREL; HEPARIN FRACTION;

ADULT; ARTICLE; CASE REPORT; CORONARY ARTERY THROMBOSIS; CORONARY CARE UNIT; CORONARY STENT; DESENSITIZATION; DRESS SYNDROME; DRUG FORMULATION; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRURITUS; RASH; SKIN EDEMA;

EID: 38349101320     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03086112     Document Type: Article

References (15)

1. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Plateletactive drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl):234S-264S.
2. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21.
3. Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K, et al. Thirty day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005;45:947-53.
4. Gowda RM, Misra D, Khan IA. Hypersensitivity skin rash: an adverse drug reaction to clopidogrel loading dose. Int J Cardiol 2004;95:333.
5. Comert A, Akgun S, Civelek A, Kavala M, Sarigül S, Yildirim T, et al. Clopidogrel-induced hypersensitivity syndrome associated with febrile pancytopenia. Int J Dermatol 2005;44:882-4.
6. Doogue MP, Begg EJ, Bridgman P. Clopidogrel Hypersensitivity Syndrome With Rash, Fever, and Neutropenia. Mayo Clin Proc 2005;80:1386-70.
7. Ten Berg JM, van Werkum JW, Heestermans AACM, Jaarsma W, Hautvast RMA, den Heijer P, et al. Antiplatelet therapy in patients undergoing coronary stenting - the risk of late stent thrombosis. Neth Heart J 2006;14:297-300.
8. Van Werkum JW, Heestermans AACM, Jaarsma W, Hautvas RWM, de Boer MJ, ten Berg JM. Trombose van een coronaire stent na het staken van behandeling met clopidogrel. Ned Tijdschr Geneeskd 2006;150:863-8.
9. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
10. World Health Organization: Adverse events following immunization (AEFI): causality assessment. http://www.who.int/vaccinesdocuments/DocsPDF05/815.pdf.
11. Szto GY, Linnemeier TJ, Ball MW. Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. Am J Cardiol 1999;83:138-9.
12. Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitisation procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol 2005;95:509-10.
13. Camara MG, Almeda FQ. Clopidogrel (Plavix) desensitisation: a case series. Cathet Cardiovasc Intervent 2005;65:525-7.
14. Lee-Wong M, Gadhvi D, Resnick S. Clopidogrel desensitization. Ann Allergy Asthma Immunol 2006;96:756-7.
15. Walker NE, Fasano MB, Horwitz PA. Rapid Communication: Desensitization for the Management of Clopidogrel Hypersensitivity: Initial Clinical Experience. J Invasive Cardiol 2006;18:341-44.